References
- Iyer L, King CD, Whitington PF et al. Genetic predispo-sition to the metabolism of irinotecan (CPT-11). Role of uri-dine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101 (4): 847-854.
- Gupta E, Lestingi TM, Mick R et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54 (14): 3723–3725.
- Ando Y, Saka H, Asai G et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998; 9 (8): 845-847.
- Wasserman E, Myara A, Lokiec F et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8 (10): 1049-1051.
- Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382–8.
- Sai K, Saeki M, Saito Y et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with can-cer. Clin Pharmacol Ther 2004; 75: 501–15.
- Komatsu Y, Takei M, Kato T et al. Phase VII study of irinotecan (irinotecan) combined with 1-leucovorin (l-LV) and 5FU in patients with advanced colorectal cancer. The 18th UICC International Cancer Congress Abstract: 962
- de Arruda M, Lyamichev VI, Eis PS et al. Invader tech-nology for DNA and RNA analysis: principles and applica-tions. Expert Rev Mol Diagn 2002; 2: 487–496.
- Mort A, Sarashina T, Yoneyama M. Development of gene diagnosis contributing to personalized medicine - Focusing on test for polymorphism relating to side effects of irinotecan. Med Sci Digest 2003; 29: 46–51
- Akaba K, Kimura T, Sasaki A et al. Neonatal hyper-bilirubinemia and mutation of the bilirubin uridine diphos-phate-glucuronosyltransferase gene. Biochem Mol Biol Int 1998; 46: 21–26.
- Maruo Y, Nishizawa K, Sato H et al. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyl-transferase polymorphism. Pediatrics 1999; 103: 1224–1227.
- Saltz LB, Cox JV, Blanke C?et al. Irinotecan plus fluo-rouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 28: 905–914.
- Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluo-rouracil alone as first-line treatment for metastatic colorectal cancer. Lancet 2000; 25: 1041–1047.
- Saijo N. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan. Ann NY Acad Sci 1996; 13: 292–305.
- Ando Y, Saka H, Ando M et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921–6926.